Bioreducible Phosphonoamidate Pro-drug Inhibitor of Enolase: Proof of Concept Study.
Ontology highlight
ABSTRACT: Glycolysis inhibition remains aspirational in cancer therapy. We recently described a promising phosphonate inhibitor of enolase for cancers harboring homozygous deletions of ENO1. Here, we describe the application of a nitroheterocycle phosphonoamidate pro-drug pair to capitalize on tumor hypoxia. This bioreducible prodrug exhibits greater-than 2-fold potency under hypoxic conditions compared to normoxia and exhibits robust stability in biological fluids. Our work provides strong in vitro proof-of-concept for using bioreduction as a pro-drug delivery strategy in the context of enolase inhibition.
SUBMITTER: Yan VC
PROVIDER: S-EPMC7357215 | biostudies-literature |
REPOSITORIES: biostudies-literature
ACCESS DATA